Since there is a better understanding of the molecular structure and its biological properties, the FcRn possesses an attractive profile in treating myasthenia gravis and other autoimmune disorders whereby the autoantibodies can be reduced by blocking the FcRn. The gene discussed is FCGRT; the disease is myasthenia gravis.